TARS — Tarsus Pharmaceuticals, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-10-16.
Performance
Technicals
Others in Healthcare
Measured signals that fired on TARS
| date | signal | measured base rate |
|---|---|---|
| 2026-08-07 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-15 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-07-14 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-10 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-24 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-14 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-17 | Azamian Bobak R. President/CEO and Board Chair | Open-market sale 10b5-1 plan | 5.4K | 61.81 | 334.9K |
| 2026-06-17 | Azamian Bobak R. President/CEO and Board Chair | Open-market sale 10b5-1 plan | 4.6K | 61.24 | 280.6K |
| 2026-06-16 | Farrow Jeffrey S See Remarks | Open-market sale | 14.4K | 60.95 | 877.4K |
| 2026-06-15 | LINK WILLIAM J PHD Director | Open-market sale 10b5-1 plan | 10.6K | 61.97 | 655.1K |
| 2026-06-15 | Goodrich Katherine Director | Open-market sale 10b5-1 plan | 3.0K | 62.08 | 183.4K |
| 2026-06-15 | LINK WILLIAM J PHD Director | Open-market sale 10b5-1 plan | 1.9K | 62.94 | 121.3K |
| 2026-06-15 | Farrow Jeffrey S See Remarks | Option exercise | 27.9K | — | — |
| 2026-06-12 | Goodrich Katherine Director | Option exercise | 3.0K | — | — |
| 2026-06-12 | Goldberg Andrew D. Director | Option exercise | 3.0K | — | — |
| 2026-06-12 | CHAUDHURI BHASKAR Director | Option exercise | 3.0K | — | — |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Deep Track Capital, LP | 252.5M | 3.6M |
| BlackRock, Inc. | 249.2M | 3.6M |
| RTW INVESTMENTS, LP | 234.7M | 3.3M |
| Paradigm Biocapital Advisors LP | 179.7M | 2.6M |
| JANUS HENDERSON GROUP PLC | 157.2M | 2.2M |
| MORGAN STANLEY | 136.4M | 1.9M |
| VANGUARD CAPITAL MANAGEMENT LLC | 123.5M | 1.8M |
| JENNISON ASSOCIATES LLC | 120.1M | 1.7M |
| Assenagon Asset Management S.A. | 89.8M | 1.3M |
| BANK OF AMERICA CORP /DE/ | 83.8M | 1.2M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
Ask the AI about TARS
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →